Edit |   |
---|---|
Antigenic Specificity | CD4 [CE9.1 (Clenoliximab)] |
Clone | polyclonal |
Host Species | Human |
Reactive Species | human, chimpanzee |
Isotype | n/a |
Format | Protein A purified |
Size | 0.2 mg |
Concentration | n/a |
Applications | ELISA (EIA), Flow Cytometry (FC/FACS), Block, SPR, Immunohistochemistry (IHC) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 ug/ml. Recombinant monoclonal antibody to CD4. Manufactured using a Recombinant Platform with variable regions (i.e. specificity) from the hybridoma CE9.1 (Clenoliximab). NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. |
Immunogen | Immunogen: Domain 1 of human CD4. Chimeric Use Statement: NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. |
Other Names | [p55; T cell surface antign T4/Leu-3.], [CD4; CD4; CD4mut] |
Gene, Accession # | [CD4], Gene ID: 920, UniProt: P01730 |
Catalog # | MBS488199 |
Price | $425 |
Order / More Info | CD4 [CE9.1 (Clenoliximab)] Antibody from MYBIOSOURCE INC. |
Product Specific References | Newman et al. Primatization of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology (NY). 1992 Nov; 10(11):1455-60. PMID:1369023 |